News
RIGL
1.250
+10.62%
0.120
Rigel Pharmaceuticals Granted Four U.S. Patents: RIP1 inhibitory compounds and methods for making and using the same; Pyrazole compounds and methods for making and using the compounds; Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations; RIP1 inhibitory compounds and methods for making and using the same
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5588&f=G&l=50&d=PTXT&p=112&S1=20220628&OS=20220628&RS=20220628
Benzinga · 4d ago
Anebulo, Tenon top healthcare gainers; BioSig, Rigel lead losers' pack
Gainers: Anebulo Pharmaceuticals (ANEB) +32%. Tenon Medical (TNON) +19%. PolarityTE (PTE) +14%. TRACON Pharmaceuticals (TCON) +14%. Bausch Health (BHC) +13%. Losers: BioSig Technologies (BSGM) -26%. Rigel Pharmaceuticals (RIGL) -8%. Valneva (VALN) -8%. Mer...
Seekingalpha · 06/24 14:05
BRIEF-Rigel Pharmaceuticals Inc - Received A Paragraph Iv Certification Notice Letter From Annora Pharma Private Limited
reuters.com · 06/23 20:30
Rigel Pharmaceuticals Received Notice Letter From Annora Pharma Private Limited; Annora Submitted An Abbreviated New Drug Application To FDA Seeking Authorization From FDA To Manufacture, Use Or Sell A Generic Version Of Tavalisse In U.S.
On June 23, 2022, Rigel Pharmaceuticals, Inc. (the “Company”) announced that it has received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Annora Pharma Private
Benzinga · 06/23 20:25
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
F-star, Valneva top healthcare gainers; Applied Therapeutics, Mereo lead losers' pack
Gainers: F-star Therapeutics FSTX +57%. Valneva VALN +23%. Nutriband NTRB +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics APLT -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) -12%. bluebird bio (...
Seekingalpha · 06/23 14:04
RIGL, REV and BOXD among pre market gainers
Ocean Bio-Chem (OBCI) +115%to acquire Ocean Bio-Chem in ~$125M all-cash deal. Revlon (REV) +29%. Codex DNA (DNAY) +26%. Boxed (BOXD) +19%. Green Giant (GGE) +10%. Comera Life Sciences Holdings (CMRA)
Seekingalpha · 06/22 12:13
ACADIA Pharmaceuticals, GeoPark, Gran Tierra Energy among premarket losers' pack
Fujian Blue Hat Interactive Entertainment Technology (BHAT) -45%. ACADIA Pharmaceuticals (ACAD) -33% as trading resumes after FDA snub for antipsychotic drug. Addex Therapeutics (ADXN) -11%. Kazia Therapeutics (KZIA) -7%. Gran Tierra Energy
Seekingalpha · 06/21 12:24
The President of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Raul Rodriguez, Just Bought 521% More Shares
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders (or potential shareholders) will be happy to see that the...
Simply Wall St. · 06/16 10:18
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
Zacks · 06/15 17:26
3 Stocks Under $1 Insiders Are Buying
The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and trad...
Benzinga · 06/14 12:22
Insider Buy: Rigel Pharmaceuticals
MT Newswires · 06/13 17:32
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
Zacks · 06/09 16:48
Rigel Pharma downgraded at several street firms following anemia study failure
Several more Street firms have downgraded Rigel Pharmaceuticals (NASDAQ:RIGL) in the wake of the company's phase 3 trial failure of fostamatinib. Citi downgraded the stock to neutral as it says
Seekingalpha · 06/09 14:17
Expert Ratings for Rigel Pharmaceuticals
Rigel Pharmaceuticals (NASDAQ:RIGL) has observed the following analyst ratings within the last quarter:
Benzinga · 06/09 14:00
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 06/09 11:26
BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating
MT Newswires · 06/09 10:48
18 Stocks Moving in Thursday's Pre-Market Session
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday.
Benzinga · 06/09 10:13
B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating
MT Newswires · 06/09 09:02
--Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7
MT Newswires · 06/09 07:29
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).